

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
|--|

At consultation, an equality issue was raised by the charity Leukaemia Care. They were concerned that the severity modifier may disadvantage older people at the end of life. The committee was satisfied that its approach had not disadvantaged older people in this appraisal. No other equality issues were raised.

- | |
|--|
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

No

- | |
|---|
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
|---|

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee's consideration of whether the severity modifier disadvantaged older people, and its conclusions that it does not, is noted in the Equality section of the final draft guidance.

Approved by Associate Director (name): Ian Watson

Date: 01 May 2024